A to Z / Pigmentation
Melanotan I
Also known as Afamelanotide, Scenesse, NDP-MSH.
Best known for The melanotan that became an approved medicine
Evidence★★★★☆
Safety dataModerately characterised
Route Implant (approved) · injectable (unregulated supply)
United StatesFDA approved (Scenesse, narrow indication)
AustraliaSchedule 4; Scenesse ARTG-registered
as at 16 September 2026
What it is
Melanotan I, afamelanotide, is a synthetic analogue of alpha-melanocyte stimulating hormone. It completed the full path of development and is an approved medicine, available as Scenesse, for a rare genetic photosensitivity disorder. Melanotan II did not reach that stage.
What the full entry covers
The book carries the rest of this entry:
- Where the research stands, with every claim cited
- What people commonly ask, and what the research shows so far
- Dosing in four labelled bands, described and not recommended
- Side effects, serious risks, cautions and interactions
- Questions to discuss with your doctor
- How it compares with Melanotan II, PT-141
Related entries
A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.
This page describes what is known and not known about Melanotan I. It is not medical advice and not a recommendation to use it.